The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
Open accessAbstract
Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of Cachectin (Tumor Necrosis Factor) Synthesis: Mechanisms of Endotoxin Resistance
Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., & Cerami, A. (1986) · Science · doi:10.1126/science.3754653 · Cited by 1,268
Waage, A., Brandtzaeg, P., Halstensen, A., Kierulf, P., & Espevik, T. (1989) · The Journal of experimental medicine · doi:10.1084/jem.169.1.333 · Cited by 1,173
Tumor Necrosis Factor and Interleuktn-1 in the Serum of Children with Severe Infectious Purpura
Girardin, E., Grau, G. E., Dayer, J.-M., Roux-Lombard, P., the J5 Study Group*, & Lambert, P.-H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198808183190703 · Cited by 737
Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.
Tracey, K. J., Wei, H., Manogue, K. R., Fong, Y., Hesse, D. G., Nguyen, H. T., Kuo, G. C., Beutler, B., Cotran, R. S., & Cerami, A. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.3.1211 · Cited by 730
Lähdevirta, J., Maury, C. P. J., Teppo, A.-M., & Repo, H. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90576-1 · Cited by 718
Landegren, U. (1984) · Journal of Immunological Methods · doi:10.1016/0022-1759(84)90477-0 · Cited by 652
Tumors secreting human TNF/cachectin induce cachexia in mice
Oliff, A., Defeo-Jones, D., Boyer, M., Martinez, D., Kiefer, D., Vuocolo, G., Wolfe, A., & Socher, S. H. (1987) · Cell · doi:10.1016/0092-8674(87)90028-6 · Cited by 640
RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PARASITIC INFECTIONS
Scuderi, P., Lam, K., Ryan, K., Petersen, E., Sterling, K., Finley, P., Ray, C. G., Slymen, D., & Salmon, S. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92007-6 · Cited by 458
EVIDENCE FOR TUMOUR NECROSIS FACTOR/CACHECTIN PRODUCTION IN CANCER
Balkwill, F., Burke, F., Talbot, D., Tavernier, J., Osborne, R., Naylor, S., Durbin, H., & Fiers, W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91850-2 · Cited by 418
Evidence that tumor necrosis factor has an important role in antibacterial resistance.
Havell, E. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.9.2894 · Cited by 405
Finkelman, F. D., Katona, I. M., Urban, J. F., Snapper, C. M., Ohara, J., & Paul, W. E. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9675 · Cited by 349
Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis.
Barnes, P. F., Fong, S. J., Brennan, P. J., Twomey, P. E., Mazumder, A., & Modlin, R. L. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.1.149 · Cited by 310
The Saga of Thalidomide: Neuropathy to Embryopathy, with Case Reports of Congenital Anomalies
Mellin, G. W., & Katzenstein, M. (1962) · New England Journal of Medicine · doi:10.1056/nejm196212062672305 · Cited by 252
The Saga of Thalidomide: Neuropathy to Embryopathy, with Case Reports of Congenital Anomalies
Mellin, G. W., & Katzenstein, M. (1962) · New England Journal of Medicine · doi:10.1056/nejm196212132672407 · Cited by 224
Regulation of the expression of IL-6 in human monocytes.
Navarro, S., Debili, N., Bernaudin, J. F., Vainchenker, W., & Doly, J. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.12.4339 · Cited by 163
Wallis, R. S., Amir-Tahmasseb, M., & Ellner, J. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.9.3348 · Cited by 158
Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens.
Wallis, R. S., Fujiwara, H., & Ellner, J. J. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.1.193 · Cited by 87
Bursten, S. L., Locksley, R. M., Ryan, J. L., & Lovett, D. H. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113755 · Cited by 57
Thalidomide--effect on T cell subsets as a possible mechanism of action.
Moncada, B., Ml, B., González‐Amaro, R., Urbina, R., & Ce, L. (1985) · PubMed · Cited by 45
Cited by
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Anti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Metadata
- Authors
- Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1991-03-01
- Volume
- 173
- Issue
- 3
- Pages
- 699-703
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2162559503
- Cited by
- 1,192
- References
- 19
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.